101 related articles for article (PubMed ID: 12722551)
1. Statins: maid-of-all-work in cardiovascular diseases!
Nalbone G; Bernot D; Peiretti F; Alessi MC
Arch Mal Coeur Vaiss; 2003 Mar; 96(3):207-13. PubMed ID: 12722551
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of HMG-CoA reductase inhibitors.
Bocan TM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of statins and related pharmacological experimental approaches.
Alegret M; Silvestre JS
Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation.
Arnaud C; Mach F
Arch Mal Coeur Vaiss; 2005 Jun; 98(6):661-6. PubMed ID: 16007821
[TBL] [Abstract][Full Text] [Related]
5. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
März W; Köenig W
J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of HMG-CoA reductase inhibitors.
Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic effects of statins and related pharmacological experimental approaches.
Alegret M; Silvestre JS
Timely Top Med Cardiovasc Dis; 2007 Apr; 11():E10. PubMed ID: 17473899
[TBL] [Abstract][Full Text] [Related]
9. Statins and their role in vascular protection.
Mason JC
Clin Sci (Lond); 2003 Sep; 105(3):251-66. PubMed ID: 12793855
[TBL] [Abstract][Full Text] [Related]
10. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
11. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
12. Effects of statins on endothelium and endothelial progenitor cell recruitment.
Walter DH; Dimmeler S; Zeiher AM
Semin Vasc Med; 2004 Nov; 4(4):385-93. PubMed ID: 15861319
[TBL] [Abstract][Full Text] [Related]
13. Antioxidative effects of statins.
Adam O; Laufs U
Arch Toxicol; 2008 Dec; 82(12):885-92. PubMed ID: 18670762
[TBL] [Abstract][Full Text] [Related]
14. [Do the pleiotropic effects of statins have a clinical significance?].
Vergès B
Arch Mal Coeur Vaiss; 2004 Dec; 97(12):1231-5. PubMed ID: 15669365
[TBL] [Abstract][Full Text] [Related]
15. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
Packard C
Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
[TBL] [Abstract][Full Text] [Related]
16. Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
Kerst LL; Mauro VF
Ann Pharmacother; 2004 Jun; 38(6):1060-4. PubMed ID: 15121997
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products.
Liang YJ; Shyu KG; Wang BW; Lai LP
Cardiology; 2008; 110(3):182-90. PubMed ID: 18057884
[TBL] [Abstract][Full Text] [Related]
18. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
19. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
20. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Bleske BE; Nicklas JM; Bard RL; Brook RD; Gurbel PA; Bliden KP; Rajagopalan S; Pitt B
J Am Coll Cardiol; 2006 Jan; 47(2):338-41. PubMed ID: 16412857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
